Information about the expected shortage of the medicinal product Anexate 0.5 mg/5 ml solution for injection or infusion (flumazenil)
14.08.2013
Roche d.o.o., the marketing authorisation holder for the medicinal product Anexate 0.5 mg/5 ml solution for injection or infusion (flumazenil), has informed the Agency for Medicinal Products and Medical Devices about the expected shortage of the aforementioned medicine on the Croatian market. The shortage is due to manufacturing problems.
The normalisation of the supply chain is expected by the end of October 2013. There will be another medicinal product available from the same therapeutic group, with the same active substance and pharmaceutical form for the treatment of Croatian patients.
